Low monocytes shows a huge improvement and under65 is significant.
I don’t think the market fully appreciates these results and the monetary potential. Everyone is looking for the silver bullet, when the reality is different bullets for different patient groups.
At a minimum, if Efti increases life expectancy by nearly two years in 20% of mbc patients and providing better quality of life then it’s a BLOCKBUSTER drug. No ifs-or buts.
And that is only scratching the surface of Efti potential.
I’ll be referring to Efti as a blockbuster in the making from now on.
Low monocytes shows a huge improvement and under65 is...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
0.003(0.78%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.3¢ | 32.0¢ | $96.18K | 300.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14975 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 182325 | 10 |
View Market Depth
| Last trade - 10.28am 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |